News
-
-
-
COMMUNIQUÉ DE PRESSE
Siltronic AG with preliminary financial figures: Targets for 2025 achieved despite challenging conditions
Siltronic AG achieves 2025 targets with preliminary financial figures despite challenging conditions. Sales at EUR 1,347 million with 4.7% decline. EBITDA margin reaches 23.5% -
COMMUNIQUÉ DE PRESSE
Sartorius Stedim Biotech réalise une croissance rentable importante en 2025 et maintient des perspectives positives
Sartorius Stedim Biotech réalise une croissance rentable en 2025 et maintient des perspectives positives. Chiffre d'affaires en hausse de 9,6% à taux de change constants. EBITDA à 914 millions d'euros. Perspectives de croissance rentable pour 2026 -
COMMUNIQUÉ DE PRESSE
Sartorius Stedim Biotech achieves considerable profitable growth in 2025 and maintains positive outlook
Sartorius Stedim Biotech achieves significant profitable growth in 2025 with unaudited sales revenue up 9.6% in constant currencies. Management expects continued growth in 2026 -
COMMUNIQUÉ DE PRESSE
Medacta Group SA: Medacta Group reports continued significant above-market revenue growth of 18.5% in constant currency in 2025
Medacta Group SA reports 18.5% revenue growth in 2025, with strong performance in all geographic markets and business lines. New jobs created to drive further expansion -
-
COMMUNIQUÉ DE PRESSE
Newron Notes Publication Highlighting Clinically Meaningful Benefits of Evenamide as an Adjunctive Treatment in Schizophrenia
Newron Pharmaceuticals S.p.A. announces publication highlighting Evenamide as adjunctive treatment in schizophrenia. Scientific evidence supports unique approach -
-
